Monthly information on share capital and company voting rights
Cellectis announced its share and voting rights update as of October 31, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellectis announced its share and voting rights update as of October 31, 2021. The total number of shares in circulation is 45,475,310, while the total number of voting rights stands at 51,076,779. As a gene editing company, Cellectis focuses on CAR-T therapies for oncology and has 21 years of expertise in the field. Its approach includes off-the-shelf gene-edited CAR T-cells and a new platform targeting hemopoietic stem cells for various diseases. Cellectis is listed on Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Positive
- Cellectis has a total of 45,475,310 shares in circulation, indicating a stable equity structure.
- The company reported 51,076,779 voting rights, reflecting shareholder engagement.
Negative
- None.
Details
News Market Reaction – CLLS
The recorded move for CLLS in the trading session of this news was -3.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
(Article 223-16 of General Regulation of the French financial markets authority)
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 10/31/2021 | 45,475,310 | 51,076,779 |
About Cellectis
Cellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs.
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomial storage diseases.
Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
For more information, visit www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.
For further information, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com
Investor Relation contact:
Eric Dutang, Chief Financial Officer, +1 (646) 630 1748, investor@cellectis.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.